Trial Profile

Phase 1b/2a Evaluation of the Safety and Tolerability of SYN-004 in Adult Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Recipients

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ribaxamase (Primary) ; Cefepime; Meropenem; Piperacillin/tazobactam
Indications Graft-versus-host disease
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors Theriva Biologics

Most Recent Events

17 Mar 2026 Planned End Date changed from 1 Dec 2026 to 30 Sep 2030.
17 Mar 2026 Planned primary completion date changed from 1 Dec 2025 to 30 Sep 2029.
13 Oct 2025 According to Theriva Biologics media release, data from this study to be presented at Infectious Diseases Week (IDWeek) 2025 Annual Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com